doi:10.3969/j.issn.1673-8640.2016.010.013

Abstract

CLC Number:

R446.1

Figures/Tables 6

References 16

[1]	CLEC'H C,FERRIERE F,KAROUBI P,et al. Diagnostic and prognostic value of procalcitonin in patients with septic shock[J]. Crit Care Med,2004,32(5):1166-1169.
[2]	KARLSSON S,HEIKKINEN M,PETTILA(··) V,et al. Predictive value of procalcitonin decrease in patients with severe sepsis:a prospective observational study[J]. Crit Care,2010,14(6):R205.
[3]	CHARLES PE,LADOIRE S,AHO S,et al.Serum procalcitonin elevation in critically ill patients at the onset of bacteremia caused by either Gram negative or Gram positive bacteria[J]. BMC Infect Dis,2008,8:38.
[4]	SIMON L,GAUVIN F,AMRE DK,et al.Serum procalcitonin and C-reactive protein levels as markers of bacterial infection:a systematic review and meta-analysis[J]. Clin Infect Dis,2004,39(2):206-217.
[5]	RINTALA EM,AITTONIEMI J,LAINE S,et al.Early identification of bacteremia by biochemical markers of systemic inflammation[J]. Scand J Clin Lab Invest,2001,61(7):523-530.
[6]	JONES AE,FIECHTL IF,BROWN MD,et a1. Procalcitonin test in the diagnosis of bacteremia:a meta-analysis[J]. Ann Emerg Med,2007,50(1):34-41.
[7]	钟倩怡,李招云,卢国光,等. 感染性标志物预测血流感染早期诊断价值的分析[J]. 检验医学,2015,30(5):522-524.
[8]	侯伟伟,肖倩茹,江涟,等. 血清降钙素原作为菌血症预示因子临床价值的研究[J]. 检验医学,2014,29(8):802-805.
[9]	HAWKINS CA,COLLIGNON P,ADAMS DN,et al.Profound lymphopenia and bacteraemia[J]. Intern Med J,2006,36(6):385-388.
[10]	JILMA B,BLANN A,PERNERSTORFER T,et al.Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin[J]. Am J Respir Crit Care Med,1999,159(3):857-863.
[11]	ZAHOREC R.Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill[J]. Bratisl Lek Listy,2001,102(1):5-14.
[12]	VINCENT JL,MORENO R,TAKALA J,et al.The SOFA(sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the working group on sepsis-related problems of the European society of intensive care medicine[J]. Intensive Care Med,1996,22(7):707-710.
[13]	GIBSON PH,CROAL BL,CUTHBERTSON BH,et al.Preoperative neutrophil-lymphocyte ratio and outcome from coronary artery bypass grafting[J]. Am Heart J,2007,154(5):995-1002.
[14]	HALAZUN KJ,ALDOORI A,MALIK HZ,et al.Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases[J]. Eur J Surg Oncol,2008,34(1):55-60.
[15]	TAMHANE UU,ANEJA S,MONTGOMERY D,et al.Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome[J]. Am J Cardiol,2008,102(6):653-657.
[16]	HALAZUN KJ,HARDY MA,RANA AA,et al.Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma[J]. Ann Surg,2009,250(1):141-151.

组别	例数	WBC（×10⁹/L）	血红蛋白（g/L）	血小板（×10⁹/L）	Neu（×10⁹/L）	Neu百分比（%）
血流感染组	144	12.32±6.22	103.98±24.38	189.37±105.24	10.87±6.12	84.91±10.11
对照组	140	9.76±4.80	107.27±28.09	210.77±97.48	8.25±8.09	79.48±9.83
t值		4.378	1.146	1.898	3.394	4.942
P值		0.000	0.253	0.059	0.001	0.000
组别	例数	Lym（×10⁹/L）	Lym百分比（%）	NLR	PCT（ng/mL）	CRP（mg/L）
血流感染组	144	0.79（0.49~1.13）	6.70（4.30~12.40）	12.90（6.54~21.20）	1.69（0.43~7.45）	81.15±65.09
对照组	140	1.08（0.73~1.58）	13.25（7.40~19.37）	5.97（3.45~11.74）	0.26（0.05~0.69）	83.08±60.30
t值		4.740	6.610	6.768	2.134	0.183
P值		0.000	0.000	0.000	2.134	0.855

组别	例数	WBC（×10⁹/L）	血红蛋白（g/L）	血小板（×10⁹/L）	Neu（×10⁹/L）	Neu百分比（%）
血流感染组	144	12.32±6.22	103.98±24.38	189.37±105.24	10.87±6.12	84.91±10.11
对照组	140	9.76±4.80	107.27±28.09	210.77±97.48	8.25±8.09	79.48±9.83
t值		4.378	1.146	1.898	3.394	4.942
P值		0.000	0.253	0.059	0.001	0.000
组别	例数	Lym（×10⁹/L）	Lym百分比（%）	NLR	PCT（ng/mL）	CRP（mg/L）
血流感染组	144	0.79（0.49~1.13）	6.70（4.30~12.40）	12.90（6.54~21.20）	1.69（0.43~7.45）	81.15±65.09
对照组	140	1.08（0.73~1.58）	13.25（7.40~19.37）	5.97（3.45~11.74）	0.26（0.05~0.69）	83.08±60.30
t值		4.740	6.610	6.768	2.134	0.183
P值		0.000	0.000	0.000	2.134	0.855

项目	ROC曲线下面积	标准误	P值	95%可信区间
项目	ROC曲线下面积	标准误	P值	下限	上限
WBC	0.658	0.032	0.000	0.594	0.721
Neu	0.702	0.031	0.000	0.641	0.763
Neu百分比	0.707	0.031	0.000	0.648	0.767
NLR	0.740	0.029	0.000	0.682	0.797
PCT	0.775	0.028	0.000	0.721	0.829
Neu百分比/Lym百分比比值	0.738	0.029	0.000	0.681	0.796
Lym	0.653	0.030	0.000	0.595	0.712
Lym百分比	0.713	0.028	0.000	0.658	0.768

项目	ROC曲线下面积	标准误	P值	95%可信区间
项目	ROC曲线下面积	标准误	P值	下限	上限
WBC	0.658	0.032	0.000	0.594	0.721
Neu	0.702	0.031	0.000	0.641	0.763
Neu百分比	0.707	0.031	0.000	0.648	0.767
NLR	0.740	0.029	0.000	0.682	0.797
PCT	0.775	0.028	0.000	0.721	0.829
Neu百分比/Lym百分比比值	0.738	0.029	0.000	0.681	0.796
Lym	0.653	0.030	0.000	0.595	0.712
Lym百分比	0.713	0.028	0.000	0.658	0.768

项目	敏感性	特异性	阳性预测值	阴性预测值
PCT	55.2	85.0	78.6	65.5
NLR	57.3	80.7	75.5	65.6
NLR+PCT	67.1	76.4	73.8	69.4

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 6

References 16

Related Articles 15

Recommended Articles

Metrics

[1]	GAO Zikang, CHEN Jing. Construction of a nomogram prediction model for the prognosis of patients with depressive disorder based on the characteristics of peripheral blood lymphocyte subsets [J]. Laboratory Medicine, 2025, 40(12): 1146-1152.
[2]	WANG Tian, ZHANG Yun, BAI Yi, ZHAI Weibin, ZHAO Hai. Roles of PIV，SII and NPAR in the diagnosis of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites [J]. Laboratory Medicine, 2025, 40(12): 1153-1158.
[3]	HUANG Ting, XU Yan, SHI Qingxing, PENG Ying. Roles of miR-944 and MARCH7 mRNA in prognosis assessment of non-small cell lung cancer patients [J]. Laboratory Medicine, 2025, 40(12): 1159-1164.
[4]	LI Minghong, MIN Cuili, GUO Qingbo, MA Lujuan. Predictive roles of serum 25（OH）D and SAA for the response to immunosuppressive therapy in autoimmune hepatitis [J]. Laboratory Medicine, 2025, 40(12): 1165-1170.
[5]	ZHEN Di, JIA Bin, MENG Xianyi. Roles of serum sPD-1 and sTWEAK levels in patients with ulcerative colitis in disease monitoring and prognosis assessment [J]. Laboratory Medicine, 2025, 40(12): 1171-1176.
[6]	ZHAO Yilin, XU Yan, YIN Hui. Roles of serum miR-145-5p，miR-200C-3p and miR-1290 in prognosis assessment of patients with papillary thyroid carcinoma [J]. Laboratory Medicine, 2025, 40(12): 1177-1182.
[7]	LI Song, XIANG Xu. Risk factors for poor prognosis in elderly patients with severe fever and thrombocytopenia syndrome and their clinical significance [J]. Laboratory Medicine, 2025, 40(12): 1183-1189.
[8]	CHANG Nan, WEI Yali, LU Qifeng, LI Tian, HOU Tingting, LI Yuan, ZHU Mengyu, SHEN Yajuan. A machine learning early warning model for acute promyelocytic leukemia based on blood cell analyzer parameters [J]. Laboratory Medicine, 2025, 40(12): 1190-1196.
[9]	. [J]. Laboratory Medicine, 2025, 40(12): 1197-1202.
[10]	. [J]. Laboratory Medicine, 2025, 40(12): 1216-1221.
[11]	. [J]. Laboratory Medicine, 2025, 40(12): 1222-1226.
[12]	BAO Wen. Application and prospect of microsatellite instability determination in tumor diagnosis and treatment [J]. Laboratory Medicine, 2025, 40(12): 1227-1231.
[13]	XIONG Ying, GUO Wei. From generic to personalized：the evolution and frontiers of indirect methods for establishing reference interval [J]. Laboratory Medicine, 2025, 40(11): 1035-1041.
[14]	CHEN Yanqin, FAN Lina, YANG Dagan. Six indirect method algorithms for establishing the reference range of serum cystatin C for adults in Hangzhou and consistency analysis [J]. Laboratory Medicine, 2025, 40(11): 1047-1052.
[15]	LIU Chunyan, NIU Shumin, DENG Zhaohui, LIANG Mengjie, ZHANG Xin. Establishing the reference ranges for AFP，CEA，CA72-4 and CA19-9 in Urumqi region by indirect method [J]. Laboratory Medicine, 2025, 40(11): 1053-1058.